Our top pick for
Amphastar Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Amphastar Pharmaceuticals shares (AMPH) are listed on the NASDAQ and all prices are listed in US Dollars. Amphastar Pharmaceuticals employs 1,980 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$16.54 - $22.69|
|50-day moving average||$17.83|
|200-day moving average||$18.76|
|Wall St. target price||$21.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Amphastar Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amphastar Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amphastar Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 578x. In other words, Amphastar Pharmaceuticals shares trade at around 578x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Amphastar Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.77. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amphastar Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amphastar Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $37.4 million.
The EBITDA is a measure of a Amphastar Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$349.8 million|
|Operating margin TTM||4.53%|
|Gross profit TTM||$143.3 million|
|Return on assets TTM||1.63%|
|Return on equity TTM||0.25%|
|Market capitalisation||$826.5 million|
TTM: trailing 12 months
There are currently 2.5 million Amphastar Pharmaceuticals shares held short by investors – that's known as Amphastar Pharmaceuticals's "short interest". This figure is 2.8% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Amphastar Pharmaceuticals shares can be evaluated.
Amphastar Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Amphastar Pharmaceuticals shares currently shorted divided by the average quantity of Amphastar Pharmaceuticals shares traded daily (recently around 170705.77181208). Amphastar Pharmaceuticals's SIR currently stands at 14.9. In other words for every 100,000 Amphastar Pharmaceuticals shares traded daily on the market, roughly 14900 shares are currently held short.
However Amphastar Pharmaceuticals's short interest can also be evaluated against the total number of Amphastar Pharmaceuticals shares, or, against the total number of tradable Amphastar Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amphastar Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Amphastar Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0656% of the tradable shares (for every 100,000 tradable Amphastar Pharmaceuticals shares, roughly 66 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Amphastar Pharmaceuticals.
Find out more about how you can short Amphastar Pharmaceuticals stock.
We're not expecting Amphastar Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Amphastar Pharmaceuticals's shares have ranged in value from as little as $16.54 up to $22.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amphastar Pharmaceuticals's is 0.7573. This would suggest that Amphastar Pharmaceuticals's shares are less volatile than average (for this exchange).
Amphastar Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.